Baird reiterates an 'Outperform' rating on Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), lowers price target from $30 to $27.

Baird ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE